shutterstock_1641369829_ascannio

Ascannio / Shutterstock.com

4 November 2020AmericasSarah Morgan

Gilead accuses Floridian clinics of HIV drug fraud

Gilead Sciences has claimed that a group of Florida-based healthcare clinics, pharmacies, and lab testing facilities have “wrongfully captured tens of millions of dollars” through a fraudulent programme.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Campaigners say US govt should have remdesivir patent rights

28 May 2020 The PrEP4All campaign has argued that the US government should own joint patent rights for remdesivir, the Gilead Sciences antiviral which is the only drug approved anywhere for treating COVID-19.

Gilead accused of illegally paying to delay HIV drug competition

22 September 2020 Biopharmaceutical company Gilead is being sued for allegedly scheming to prevent a generic rival from releasing a competing version of its HIV drug Truvada, according to a class action lawsuit filed by investors in the drug manufacturer.

More on this story

Campaigners say US govt should have remdesivir patent rights

28 May 2020 The PrEP4All campaign has argued that the US government should own joint patent rights for remdesivir, the Gilead Sciences antiviral which is the only drug approved anywhere for treating COVID-19.

Gilead accused of illegally paying to delay HIV drug competition

22 September 2020 Biopharmaceutical company Gilead is being sued for allegedly scheming to prevent a generic rival from releasing a competing version of its HIV drug Truvada, according to a class action lawsuit filed by investors in the drug manufacturer.

More on this story

Campaigners say US govt should have remdesivir patent rights

28 May 2020 The PrEP4All campaign has argued that the US government should own joint patent rights for remdesivir, the Gilead Sciences antiviral which is the only drug approved anywhere for treating COVID-19.

Gilead accused of illegally paying to delay HIV drug competition

22 September 2020 Biopharmaceutical company Gilead is being sued for allegedly scheming to prevent a generic rival from releasing a competing version of its HIV drug Truvada, according to a class action lawsuit filed by investors in the drug manufacturer.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent